X

Trial Profile

Phase II Study of Combination Therapy with OBP-301 and Radiotherapy in Patients with Locally Advanced Esophageal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Suratadenoturev (Primary)
Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Chugai Pharmaceutical

Most Recent Events

17 Oct 2023 Primary endpoint (L-CR (Local Complete Response) rate) has been met as per Oncolys Biopharma Media Release
17 Oct 2023 Results published in the Oncolys Biopharma Media Release
04 Aug 2023 According to a Oncolys Biopharma media release, The results for this trial are expected to be available in October 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com